Identification of potential changes in the glycosylation of existing cancer biomarkers can result in a higher level of diagnostic sensitivity and specificity.
Clusterin (Apolipoprotein J) has been implicated in renal cell carcinoma (RCC) and other types of malignancy as potential biomarker. In the present work, an automated multi-dimensional HPLC platform enabling high throughput affinity enrichment of clusterin from plasma samples was developed. Integrated with two dimensional gel electrophoresis, high purity clusterin in microgram quantities suitable for glycan characterization was isolated. The analytical platform was applied to study clusterin glycosylation in a small group of RCC patients before and after nephrectopy as a pilot study to evaluate the performance of the platform. A statistically significant decrease was observed in the levels of a bi-antennary digalactosyl disialylated (A2G2S(3)2) glycans while the levels of a core fucosylated bi-antennary digalactosyl disialylated glycan (FA2G2S(6)2) and a tri-antennary trigalactosyl disialylated glycan (A3G3S(6)2) were increased in the post-surgery plasma samples.
Written by:
Tousi F, Bones J, Iliopoulos O, Hancock WS, Hincapie M. Are you the author?
Department of Chemistry and Chemical Biology, Barnett Institute, Northeastern University, Boston, MA 02115, USA.
Reference: J Chromatogr A. 2012 Sep 21;1256:121-8.
doi: 10.1016/j.chroma.2012.07.066
PubMed Abstract
PMID: 22885037
UroToday.com Investigative Urology Section
